(688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Progress of Litigation
Filed with SSE · Stock code 688319 · · 3 pages · Chinese
Summary by 6ix AI
Chengdu Olymvax Biopharmaceuticals Inc. has announced the progress of a litigation case involving the company as a defendant and counterclaimant. The case is currently in the appeal period following a first-instance judgment that has not yet taken effect. The company warns that the final outcome of the litigation may impact its profits, but the specific effects remain uncertain until a final judgment is issued.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/688319chengdu-olymvax-biopharmaceuticals-incannouncement-on-progress-of-litigation
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Story so far
Earlier from Chengdu Olymvax Biopharmaceuticals
- Announcement on Shareholding Reduction Plan of a Director and Senior Management Member
- Niutech Signs Agreement with Global Energy Major for Waste Plastic Pyrolysis Line to Produce SAF
- Semi-annual Report for 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Pledge of Certain Shares Held by Shareholders Holding More Than 5% of the Shares
Later from Chengdu Olymvax Biopharmaceuticals
All Chengdu Olymvax Biopharmaceuticals news releasesFollow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals